Min Chu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Min Chu has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Liyong Wu
Department of Neurology, Xuanwu Hospital Capital Medical University Beijing China
5 shared publications - Haitian Nan
Department of Neurology, Xuanwu Hospital, Capital Medical University
3 shared publications Liyong Wu
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
3 shared publications- Mahesh Patel
Wockhardt Research Centre, Aurangabad, India
3 shared publications Ailing Yue
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
2 shared publicationsBirendra Pramanik
Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth NJ 07033 USA
2 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (11)
Frontal Cerebral Blood Flow Deficits in Behavioral Variant Frontotemporal Dementia: Associations With Clinical Symptoms, Peripheral Vascular Biomarkers, and Neuroimaging Measures
Aims: This study aimed to characterize regional cerebral blood flow (CBF) alterations in behavioral variant frontotemporal dementia (bvFTD), examine their associations with clinical symptoms and peripheral vascular/synaptic biomarkers, evaluate spatial concordance with gray matter volume (GMV) loss and glucose hypometabolism, and explore CBF's mediating role between biomarkers and clinical outcomes. Methods: Thirty‐five bvFTD patients and 27 matched normal controls (NC) underwent clinical assessments, ASL MRI, 18 F‐FDG PET, and structural MRI. Plasma vascular (VEGFA, PDGF‐BB) and synaptic (NPTXR, NPTX2) biomarkers were measured via the Olink platform. Statistical analyses included group comparisons, ROC analysis, multiple linear regression, and mediation analysis. Results: Compared with normal controls, bvFTD patients exhibited significantly reduced CBF in both frontal and temporal regions, which showed regional spatial concordance with GMV and FDG uptake in corresponding areas. Frontal CBF demonstrated good diagnostic accuracy and was significantly associated with multiple clinical measures including MMSE, MoCA, ADL, and behavioral scales, as well as with peripheral vascular and synaptic biomarkers. Exploratory mediation analyses suggested statistical indirect associations linking peripheral vascular biomarkers to clinical symptoms through frontal CBF and linking frontal CBF to behavioral outcomes through frontal GMV. Conclusions: BvFTD is characterized by frontotemporal hypoperfusion, with frontal CBF closely associated with cognitive, behavioral, and functional impairment. The regional concordance of ASL‐derived CBF with gray matter atrophy and glucose hypometabolism supports its potential role as an accessible, non‐invasive, and radiation‐free complementary neuroimaging biomarker. The mediation findings should be considered hypothesis‐generating because they did not remain significant after FDR correction and require validation in larger longitudinal studies.
- 1 November 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (11)
Open AccessFrontal Cerebral Blood Flow Deficits in Behavioral Variant Frontotemporal Dementia: Associations With Clinical Symptoms, Peripheral Vascular Biomarkers, and Neuroimaging Measures
Aims: This study aimed to characterize regional cerebral blood flow (CBF) alterations in behavioral variant frontotemporal dementia (bvFTD), examine their associations with clinical symptoms and peripheral vascular/synaptic biomarkers, evaluate spatial concordance with gray matter volume (GMV) loss and glucose hypometabolism, and explore CBF's mediating role between biomarkers and clinical outcomes. Methods: Thirty‐five bvFTD patients and 27 matched normal controls (NC) underwent clinical assessments, ASL MRI, 18 F‐FDG PET, and structural MRI. Plasma vascular (VEGFA, PDGF‐BB) and synaptic (NPTXR, NPTX2) biomarkers were measured via the Olink platform. Statistical analyses included group comparisons, ROC analysis, multiple linear regression, and mediation analysis. Results: Compared with normal controls, bvFTD patients exhibited significantly reduced CBF in both frontal and temporal regions, which showed regional spatial concordance with GMV and FDG uptake in corresponding areas. Frontal CBF demonstrated good diagnostic accuracy and was significantly associated with multiple clinical measures including MMSE, MoCA, ADL, and behavioral scales, as well as with peripheral vascular and synaptic biomarkers. Exploratory mediation analyses suggested statistical indirect associations linking peripheral vascular biomarkers to clinical symptoms through frontal CBF and linking frontal CBF to behavioral outcomes through frontal GMV. Conclusions: BvFTD is characterized by frontotemporal hypoperfusion, with frontal CBF closely associated with cognitive, behavioral, and functional impairment. The regional concordance of ASL‐derived CBF with gray matter atrophy and glucose hypometabolism supports its potential role as an accessible, non‐invasive, and radiation‐free complementary neuroimaging biomarker. The mediation findings should be considered hypothesis‐generating because they did not remain significant after FDR correction and require validation in larger longitudinal studies.
- 7 September 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 113 (4) , 1745-1757
Disease-specific hypometabolic epicenters in dementia: Neural networks and clinical correlations
Background: In dementia, it remains unclear how the hypometabolism pattern relates to the intrinsic network, where the disease-specific hypometabolism epicenters are located, and what the epicenter's clinical effects are. Objective: In this cross-sectional study, we aim to identify disease-specific hypometabolism epicenters in Alzheimer's disease (AD), posterior cortical atrophy (PCA), and frontotemporal dementia (FTD) using a data-driven network-based approach; to determine whether intrinsic structural and functional brain networks shape the spatial distribution of hypometabolism; and to examine the clinical relevance of epicenter hypometabolism by assessing its association with network disruption and disease-related clinical features. Methods: Disease-specific epicenters were identified using data-driven analysis in AD (n = 98), PCA (n = 40), and FTD (n = 71). Hypometabolism was measured by [ 18 F]-fluorodeoxyglucose positron emission tomography (FDG-PET). Brain regions with reduced network connectivity to the epicenter were identified, and the correlation between changes in the epicenter and clinical features was examined. Results: Regional hypometabolism was significantly correlated with that of the network-connected neighbors. The disease-specific hypometabolism epicenters were the bilateral angular gyrus in AD, the angular and middle occipital gyri in PCA, and the rectus and anterior cingulate gyri in FTD. The hypometabolism of the epicenters contributed to the disruption of the network and was correlated with clinical features. Conclusions: The hypometabolism epicenters are disease-specific and correlated with clinical features in dementia, providing insight into neuromodulation targets.
- 7 September 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 113 (4) , 1745-1757
Disease-specific hypometabolic epicenters in dementia: Neural networks and clinical correlations
Background: In dementia, it remains unclear how the hypometabolism pattern relates to the intrinsic network, where the disease-specific hypometabolism epicenters are located, and what the epicenter's clinical effects are. Objective: In this cross-sectional study, we aim to identify disease-specific hypometabolism epicenters in Alzheimer's disease (AD), posterior cortical atrophy (PCA), and frontotemporal dementia (FTD) using a data-driven network-based approach; to determine whether intrinsic structural and functional brain networks shape the spatial distribution of hypometabolism; and to examine the clinical relevance of epicenter hypometabolism by assessing its association with network disruption and disease-related clinical features. Methods: Disease-specific epicenters were identified using data-driven analysis in AD (n = 98), PCA (n = 40), and FTD (n = 71). Hypometabolism was measured by [ 18 F]-fluorodeoxyglucose positron emission tomography (FDG-PET). Brain regions with reduced network connectivity to the epicenter were identified, and the correlation between changes in the epicenter and clinical features was examined. Results: Regional hypometabolism was significantly correlated with that of the network-connected neighbors. The disease-specific hypometabolism epicenters were the bilateral angular gyrus in AD, the angular and middle occipital gyri in PCA, and the rectus and anterior cingulate gyri in FTD. The hypometabolism of the epicenters contributed to the disruption of the network and was correlated with clinical features. Conclusions: The hypometabolism epicenters are disease-specific and correlated with clinical features in dementia, providing insight into neuromodulation targets.
- 22 July 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 113 (2) , 721-733
Retinal structural and microvascular alterations as biomarkers of cerebral pathology and cognitive decline in Alzheimer's disease: An OCT/OCTA study
Background: Retinal structural and microvascular alterations detected by optical coherence tomography (OCT) and OCT angiography (OCTA) have emerged as promising biomarkers of Alzheimer's disease (AD). However, the extent to which retinal changes reflect cerebral neurodegenerative and vascular pathology and contribute to cognitive impairment remains incompletely characterized. Objective: To investigate the relationships among retinal OCT/OCTA metrics, cerebral neuroimaging markers, and global cognitive performance in patients with AD. Methods: 115 AD and 101 cognitively unimpaired controls underwent OCT/OCTA imaging, 3.0T brain magnetic resonance imaging, and neuropsychological assessment. Retinal structural measures, including peripapillary retinal nerve fiber layer (pRNFL) and ganglion cell-inner plexiform layer (GCIPL) thicknesses, and retinal microvascular densities of the superficial vascular complex (SVC) and deep vascular complex were analyzed alongside white matter hyperintensity (WMH) volume, hippocampal volume, and cerebral small vessel disease (SVD) burden. Results: Compared with controls, patients with AD exhibited significantly thinner pRNFL and GCIPL and lower SVC density (all p < 0.01). Retinal structural and microvascular alterations were associated with greater WMH burden, hippocampal atrophy, increased SVD burden, and lower Mini-Mental State Examination and Montreal Cognitive Assessment scores (all p < 0.05). Significant interactions were observed between GCIPL thickness and periventricular WMH volume in relation to cognitive performance. Mediation analyses demonstrated that WMH volume and SVD burden partially mediated the association between reduced SVC density and cognitive impairment. Conclusions: Retinal OCT/OCTA metrics are associated with cerebral neurodegenerative and vascular abnormalities and reflect cognitive dysfunction in AD, supporting their potential utility as accessible, noninvasive biomarkers for disease assessment and monitoring.
- 22 July 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 113 (2) , 721-733
Retinal structural and microvascular alterations as biomarkers of cerebral pathology and cognitive decline in Alzheimer's disease: An OCT/OCTA study
Background: Retinal structural and microvascular alterations detected by optical coherence tomography (OCT) and OCT angiography (OCTA) have emerged as promising biomarkers of Alzheimer's disease (AD). However, the extent to which retinal changes reflect cerebral neurodegenerative and vascular pathology and contribute to cognitive impairment remains incompletely characterized. Objective: To investigate the relationships among retinal OCT/OCTA metrics, cerebral neuroimaging markers, and global cognitive performance in patients with AD. Methods: 115 AD and 101 cognitively unimpaired controls underwent OCT/OCTA imaging, 3.0T brain magnetic resonance imaging, and neuropsychological assessment. Retinal structural measures, including peripapillary retinal nerve fiber layer (pRNFL) and ganglion cell-inner plexiform layer (GCIPL) thicknesses, and retinal microvascular densities of the superficial vascular complex (SVC) and deep vascular complex were analyzed alongside white matter hyperintensity (WMH) volume, hippocampal volume, and cerebral small vessel disease (SVD) burden. Results: Compared with controls, patients with AD exhibited significantly thinner pRNFL and GCIPL and lower SVC density (all p < 0.01). Retinal structural and microvascular alterations were associated with greater WMH burden, hippocampal atrophy, increased SVD burden, and lower Mini-Mental State Examination and Montreal Cognitive Assessment scores (all p < 0.05). Significant interactions were observed between GCIPL thickness and periventricular WMH volume in relation to cognitive performance. Mediation analyses demonstrated that WMH volume and SVD burden partially mediated the association between reduced SVC density and cognitive impairment. Conclusions: Retinal OCT/OCTA metrics are associated with cerebral neurodegenerative and vascular abnormalities and reflect cognitive dysfunction in AD, supporting their potential utility as accessible, noninvasive biomarkers for disease assessment and monitoring.
- 13 March 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 110 (3) , 1153-1165
Mutual effects of sleep duration and traits on the risk of dementia: A prospective study in the UK Biobank
Background: Both sleep duration and traits significantly influence cognitive health, making it crucial to identify optimal sleep patterns for preventing dementia. Objective: To investigate the mutual effects of sleep duration and sleep traits on dementia risk. Methods: This prospective study analyzed data from 359,505 participants in the UK Biobank, with baseline data collected between 2006–2010. Sleep patterns were assessed by constructing composite indicators through pairwise combinations of self-reported sleep duration and traits, including ease of getting up in the morning, chronotype, napping, daytime dozing, and use of sleep-related medications. The association between sleep patterns and dementia incidence was evaluated using Cox proportional hazards models during a mean follow-up period of 13.63 years. Results: During the follow-up, 5123 participants developed dementia. In fully adjusted models, both short (≤6 h) and long (≥9 h) sleep durations, along with unfavorable sleep traits (hard or easy getting up, morning chronotype, habitual napping, dozing, sleep-related medications use), were significantly associated with increased dementia risk (p < 0.05). Notably, long sleep duration combined with evening chronotype (HR = 1.45, 95%CI: 1.15–1.83), habitual dozing (HR = 1.57, 95%CI: 1.18–2.09), or hypnotic use (HR = 2.71, 95%CI: 1.77–4.13) exhibited the highest risks compared to optimal sleep duration with corresponding alternative sleep traits. Similarly, short sleep duration combined with habitual napping carried the highest risk of dementia (HR = 1.54, 95%CI: 1.27–1.88). Conclusions: Both sleep duration and traits are associated with dementia risk, particularly when abnormal duration interacts with unfavorable traits. These findings underscore the necessity of incorporating comprehensive sleep pattern assessments into dementia prevention strategies.
- 13 March 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 110 (3) , 1153-1165
Mutual effects of sleep duration and traits on the risk of dementia: A prospective study in the UK Biobank
Background: Both sleep duration and traits significantly influence cognitive health, making it crucial to identify optimal sleep patterns for preventing dementia. Objective: To investigate the mutual effects of sleep duration and sleep traits on dementia risk. Methods: This prospective study analyzed data from 359,505 participants in the UK Biobank, with baseline data collected between 2006–2010. Sleep patterns were assessed by constructing composite indicators through pairwise combinations of self-reported sleep duration and traits, including ease of getting up in the morning, chronotype, napping, daytime dozing, and use of sleep-related medications. The association between sleep patterns and dementia incidence was evaluated using Cox proportional hazards models during a mean follow-up period of 13.63 years. Results: During the follow-up, 5123 participants developed dementia. In fully adjusted models, both short (≤6 h) and long (≥9 h) sleep durations, along with unfavorable sleep traits (hard or easy getting up, morning chronotype, habitual napping, dozing, sleep-related medications use), were significantly associated with increased dementia risk (p < 0.05). Notably, long sleep duration combined with evening chronotype (HR = 1.45, 95%CI: 1.15–1.83), habitual dozing (HR = 1.57, 95%CI: 1.18–2.09), or hypnotic use (HR = 2.71, 95%CI: 1.77–4.13) exhibited the highest risks compared to optimal sleep duration with corresponding alternative sleep traits. Similarly, short sleep duration combined with habitual napping carried the highest risk of dementia (HR = 1.54, 95%CI: 1.27–1.88). Conclusions: Both sleep duration and traits are associated with dementia risk, particularly when abnormal duration interacts with unfavorable traits. These findings underscore the necessity of incorporating comprehensive sleep pattern assessments into dementia prevention strategies.
- Open Access
- 23 January 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (1) , e70765
Peripheral Signatures of Multidimensional Pathology in Symptomatic and Asymptomatic Creutzfeldt–Jakob Disease
Background: Plasma markers of neuronal injury in Creutzfeldt–Jakob disease (CJD) are established, but peripheral biomarkers reflecting glial activation, synaptic dysfunction, and vascular impairment remain less explored. We systematically assessed these markers in symptomatic CJD and asymptomatic PRNP mutation carriers to improve diagnosis and identify early pathophysiology. Methods: This prospective cohort study recruited CJD, frontotemporal dementia (FTD), healthy controls (HCs), and preclinical familial CJD pedigrees. Sixteen plasma proteins representing neuronal injury, glial activation, synaptic function, and vascular/BBB integrity were measured. Analyses included group differences, discriminative performance, clinical/imaging correlations, and longitudinal trajectories. Results: We enrolled 130 CJD patients, 145 FTD, 70 HCs, 16 asymptomatic PRNP carriers (4–6 years follow‐up, 4 converters), and 16 non‐carrier family controls. In symptomatic CJD, plasma NfL, t‐tau, and GFAP were strongly elevated, each showing excellent discriminative performance (AUCs > 0.93 vs. HCs and > 0.82 vs. FTD). We also observed alterations in vascular/BBB markers, with VCAM‐1 levels elevated and significantly associated with both clinical decline and DWI hyperintensity. In asymptomatic carriers, biomarker levels remained largely normal and stable preclinically. Notably, two G114V carriers showed mild pre‐symptomatic elevations in NfL and GFAP, and one exhibited a slight VCAM‐1 increase before clinical onset; all changes exceeded the 90th percentile of control values. E200K and T188K carriers showed no pre‐onset changes. Conclusions: Plasma biomarkers in CJD may reflect multisystem involvement, with neuronal markers showing strong discriminative potential and vascular proteins indicating possible BBB dysfunction. In asymptomatic carriers, minor changes may occur only near onset in those with relatively slow‐progressing mutations.
- 23 January 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (1) , e70765
Open AccessPeripheral Signatures of Multidimensional Pathology in Symptomatic and Asymptomatic Creutzfeldt–Jakob Disease
Background: Plasma markers of neuronal injury in Creutzfeldt–Jakob disease (CJD) are established, but peripheral biomarkers reflecting glial activation, synaptic dysfunction, and vascular impairment remain less explored. We systematically assessed these markers in symptomatic CJD and asymptomatic PRNP mutation carriers to improve diagnosis and identify early pathophysiology. Methods: This prospective cohort study recruited CJD, frontotemporal dementia (FTD), healthy controls (HCs), and preclinical familial CJD pedigrees. Sixteen plasma proteins representing neuronal injury, glial activation, synaptic function, and vascular/BBB integrity were measured. Analyses included group differences, discriminative performance, clinical/imaging correlations, and longitudinal trajectories. Results: We enrolled 130 CJD patients, 145 FTD, 70 HCs, 16 asymptomatic PRNP carriers (4–6 years follow‐up, 4 converters), and 16 non‐carrier family controls. In symptomatic CJD, plasma NfL, t‐tau, and GFAP were strongly elevated, each showing excellent discriminative performance (AUCs > 0.93 vs. HCs and > 0.82 vs. FTD). We also observed alterations in vascular/BBB markers, with VCAM‐1 levels elevated and significantly associated with both clinical decline and DWI hyperintensity. In asymptomatic carriers, biomarker levels remained largely normal and stable preclinically. Notably, two G114V carriers showed mild pre‐symptomatic elevations in NfL and GFAP, and one exhibited a slight VCAM‐1 increase before clinical onset; all changes exceeded the 90th percentile of control values. E200K and T188K carriers showed no pre‐onset changes. Conclusions: Plasma biomarkers in CJD may reflect multisystem involvement, with neuronal markers showing strong discriminative potential and vascular proteins indicating possible BBB dysfunction. In asymptomatic carriers, minor changes may occur only near onset in those with relatively slow‐progressing mutations.
- Open Access
- 20 January 2026
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 8 (2)
Disrupted brain topological network and its association with clinical features in posterior cortical atrophy
The characteristics of structural brain topological network alterations and their correlation with clinical features in posterior cortical atrophy (PCA) remain elusive. This study aims to explore the structural topological network alterations and their correlation with clinical features in PCA. Thirty-four patients with PCA and 34 healthy controls were enrolled in this cross-sectional study and underwent diffusion tensor imaging, structural MRI and neuropsychological assessment. The graph theory method was applied to capture the individual structural properties of the network. Partial correlation analysis was conducted to investigate the clinical relevance of the network properties. The global metrics of the structural and topological network are altered in the PCA group. The nodal metrics were changed in the occipital, parietal, temporal and frontal lobes. Global network metrics are associated with cognition and disease severity. For the node associated with apraxia, finger agnosia, left-right disorientation and agnosia for colour, face and object, we observed a similar but not identical nodal distribution, which was mainly distributed in the parietal cortex. Notably, we observed frontal nodes, including the orbital gyrus, contribute to the left-right disorientation and colour agnosia, and the rectus contributes to the object agnosia. This study helps us understand the underlying mechanism of the symptom network in PCA and provides a promising biomarker for PCA.
- 20 January 2026
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 8 (2)
Open AccessDisrupted brain topological network and its association with clinical features in posterior cortical atrophy
The characteristics of structural brain topological network alterations and their correlation with clinical features in posterior cortical atrophy (PCA) remain elusive. This study aims to explore the structural topological network alterations and their correlation with clinical features in PCA. Thirty-four patients with PCA and 34 healthy controls were enrolled in this cross-sectional study and underwent diffusion tensor imaging, structural MRI and neuropsychological assessment. The graph theory method was applied to capture the individual structural properties of the network. Partial correlation analysis was conducted to investigate the clinical relevance of the network properties. The global metrics of the structural and topological network are altered in the PCA group. The nodal metrics were changed in the occipital, parietal, temporal and frontal lobes. Global network metrics are associated with cognition and disease severity. For the node associated with apraxia, finger agnosia, left-right disorientation and agnosia for colour, face and object, we observed a similar but not identical nodal distribution, which was mainly distributed in the parietal cortex. Notably, we observed frontal nodes, including the orbital gyrus, contribute to the left-right disorientation and colour agnosia, and the rectus contributes to the object agnosia. This study helps us understand the underlying mechanism of the symptom network in PCA and provides a promising biomarker for PCA.
- 1 September 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 107 (2) , 806-818
Plasma glial fibrillary acidic protein and neurological diseases: A bidirectional Mendelian randomization study
Background: Increased glial fibrillary acidic protein (GFAP) in blood, a biomarker of reactive astrogliosis and astrocytic injury, was observed in a variety of neurological disorders. However, the causal relationship between plasma GFAP and neurological disorders remains unclear. Objective: We aim to investigate causal association between plasma GFAP levels and neurological disorders using bidirectional Mendelian randomization (MR). Methods: The genome-wide association studies for neurological disorders, including neurodegenerative diseases, neuroimmune disorders, cerebrovascular diseases, and epilepsy, were collected. Genetic variables associated with plasma GFAP levels were obtained from the UK Biobank Pharma Proteomics Project. Inverse variance weighted or Wald ratio method was used as the main analysis to assess the causal association. Results: Genetically predicted higher plasma GFAP levels were found to be associated with an increased risk of encephalitis (odds ratio [OR] = 2.52; 95% confidence interval [CI] = 1.67–3.47; p = 1.22 × 10 –5 ). Furthermore, we found that Alzheimer's disease (β = 0.05; standard error [SE] = 0.01; p = 6.63 × 10 –8 ), frontotemporal dementia (β = 0.12; SE = 0.01; p = 5.10 × 10 –16 ), and dementia with Lewy bodies (β = 0.08; SE = 0.02; p = 5.45 × 10 –5 ) were causally linked to an increase in plasma GFAP levels. Even after controlling for the influence of aging, these associations remained significant. Conclusions: Our study found that higher plasma GFAP levels may increase the risk of encephalitis, while neurodegenerative dementia may enhance the plasma GFAP levels, supporting the clinical utility of blood GFAP as a reliable biomarker in neurological diseases.
- 1 September 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 107 (2) , 806-818
Plasma glial fibrillary acidic protein and neurological diseases: A bidirectional Mendelian randomization study
Background: Increased glial fibrillary acidic protein (GFAP) in blood, a biomarker of reactive astrogliosis and astrocytic injury, was observed in a variety of neurological disorders. However, the causal relationship between plasma GFAP and neurological disorders remains unclear. Objective: We aim to investigate causal association between plasma GFAP levels and neurological disorders using bidirectional Mendelian randomization (MR). Methods: The genome-wide association studies for neurological disorders, including neurodegenerative diseases, neuroimmune disorders, cerebrovascular diseases, and epilepsy, were collected. Genetic variables associated with plasma GFAP levels were obtained from the UK Biobank Pharma Proteomics Project. Inverse variance weighted or Wald ratio method was used as the main analysis to assess the causal association. Results: Genetically predicted higher plasma GFAP levels were found to be associated with an increased risk of encephalitis (odds ratio [OR] = 2.52; 95% confidence interval [CI] = 1.67–3.47; p = 1.22 × 10 –5 ). Furthermore, we found that Alzheimer's disease (β = 0.05; standard error [SE] = 0.01; p = 6.63 × 10 –8 ), frontotemporal dementia (β = 0.12; SE = 0.01; p = 5.10 × 10 –16 ), and dementia with Lewy bodies (β = 0.08; SE = 0.02; p = 5.45 × 10 –5 ) were causally linked to an increase in plasma GFAP levels. Even after controlling for the influence of aging, these associations remained significant. Conclusions: Our study found that higher plasma GFAP levels may increase the risk of encephalitis, while neurodegenerative dementia may enhance the plasma GFAP levels, supporting the clinical utility of blood GFAP as a reliable biomarker in neurological diseases.
- Open Access
- 1 March 2024
- Published by Oxford University Press (OUP) in Brain
- Vol. 147 (9) , 3048-3058
Atrophy network mapping of clinical subtypes and main symptoms in frontotemporal dementia
Frontotemporal dementia (FTD) is a disease of high heterogeneity, apathy and disinhibition present in all subtypes of FTD and imposes a significant burden on families/society. Traditional neuroimaging analysis has limitations in elucidating the network localization due to individual clinical and neuroanatomical variability. The study aims to identify the atrophy network map associated with different FTD clinical subtypes and determine the specific localization of the network for apathy and disinhibition. Eighty FTD patients [45 behavioural variant FTD (bvFTD) and 35 semantic variant progressive primary aphasia (svPPA)] and 58 healthy controls at Xuanwu Hospital were enrolled as Dataset 1; 112 FTD patients including 50 bvFTD, 32 svPPA and 30 non-fluent variant PPA (nfvPPA) cases, and 110 healthy controls from the Frontotemporal Lobar Degeneration Neuroimaging Initiative (FTLDNI) dataset were included as Dataset 2. Initially, single-subject atrophy maps were defined by comparing cortical thickness in each FTD patient versus healthy controls. Next, the network of brain regions functionally connected to each FTD patient’s location of atrophy was determined using seed-based functional connectivity in a large (n = 1000) normative connectome. Finally, we used atrophy network mapping to define clinical subtype-specific network (45 bvFTD, 35 svPPA and 58 healthy controls in Dataset 1; 50 bvFTD, 32 svPPA, 30 nfvPPA and 110 healthy controls in Dataset 2) and symptom-specific networks [combined Datasets 1 and 2, apathy without depression versus non-apathy without depression (80:26), disinhibition versus non-disinhibition (88:68)]. We compare the result with matched symptom networks derived from patients with focal brain lesions or conjunction analysis. Through the analysis of two datasets, we identified heterogeneity in atrophy patterns among FTD patients. However, these atrophy patterns are connected to a common brain network. The primary regions affected by atrophy in FTD included the frontal and temporal lobes, particularly the anterior temporal lobe. bvFTD connects to frontal and temporal cortical areas, svPPA mainly impacts the anterior temporal region and nfvPPA targets the inferior frontal gyrus and precentral cortex regions. The apathy-specific network was localized in the orbital frontal cortex and ventral striatum, while the disinhibition-specific network was localized in the bilateral orbital frontal gyrus and right temporal lobe. Apathy and disinhibition atrophy networks resemble known motivational and criminal lesion networks, respectively. A significant correlation was found between the apathy/disinhibition scores and functional connectivity between atrophy maps and the peak of the networks. This study localizes the common network of clinical subtypes and main symptoms in FTD, guiding future FTD neuromodulation interventions.
- 1 March 2024
- Published by Oxford University Press (OUP) in Brain
- Vol. 147 (9) , 3048-3058
Open AccessAtrophy network mapping of clinical subtypes and main symptoms in frontotemporal dementia
Frontotemporal dementia (FTD) is a disease of high heterogeneity, apathy and disinhibition present in all subtypes of FTD and imposes a significant burden on families/society. Traditional neuroimaging analysis has limitations in elucidating the network localization due to individual clinical and neuroanatomical variability. The study aims to identify the atrophy network map associated with different FTD clinical subtypes and determine the specific localization of the network for apathy and disinhibition. Eighty FTD patients [45 behavioural variant FTD (bvFTD) and 35 semantic variant progressive primary aphasia (svPPA)] and 58 healthy controls at Xuanwu Hospital were enrolled as Dataset 1; 112 FTD patients including 50 bvFTD, 32 svPPA and 30 non-fluent variant PPA (nfvPPA) cases, and 110 healthy controls from the Frontotemporal Lobar Degeneration Neuroimaging Initiative (FTLDNI) dataset were included as Dataset 2. Initially, single-subject atrophy maps were defined by comparing cortical thickness in each FTD patient versus healthy controls. Next, the network of brain regions functionally connected to each FTD patient’s location of atrophy was determined using seed-based functional connectivity in a large (n = 1000) normative connectome. Finally, we used atrophy network mapping to define clinical subtype-specific network (45 bvFTD, 35 svPPA and 58 healthy controls in Dataset 1; 50 bvFTD, 32 svPPA, 30 nfvPPA and 110 healthy controls in Dataset 2) and symptom-specific networks [combined Datasets 1 and 2, apathy without depression versus non-apathy without depression (80:26), disinhibition versus non-disinhibition (88:68)]. We compare the result with matched symptom networks derived from patients with focal brain lesions or conjunction analysis. Through the analysis of two datasets, we identified heterogeneity in atrophy patterns among FTD patients. However, these atrophy patterns are connected to a common brain network. The primary regions affected by atrophy in FTD included the frontal and temporal lobes, particularly the anterior temporal lobe. bvFTD connects to frontal and temporal cortical areas, svPPA mainly impacts the anterior temporal region and nfvPPA targets the inferior frontal gyrus and precentral cortex regions. The apathy-specific network was localized in the orbital frontal cortex and ventral striatum, while the disinhibition-specific network was localized in the bilateral orbital frontal gyrus and right temporal lobe. Apathy and disinhibition atrophy networks resemble known motivational and criminal lesion networks, respectively. A significant correlation was found between the apathy/disinhibition scores and functional connectivity between atrophy maps and the peak of the networks. This study localizes the common network of clinical subtypes and main symptoms in FTD, guiding future FTD neuromodulation interventions.
- Open Access
- 6 June 2023
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 10 (7) , 1209-1218
Toward an early clinical diagnosis of MM2‐type sporadic Creutzfeldt–Jakob disease
Objective: To assess the proportion of clinically diagnosed MM2‐type sporadic Creutzfeldt–Jakob disease (sCJD) in a Chinese cohort, describe the clinical features of MM2‐cortical (MM2C) and MM2‐thalamic (MM2T) type sCJD to improve the early detection of MM2‐type sCJD.Methods: A total of 209 patients with sCJD admitted to the Xuanwu Hospital between February 2012 and August 2022 were reviewed. The patients were classified into probable MM2C, MM2T‐type sCJD, and other types of sCJD according to current clinical diagnostic criteria. Clinical and ancillary data were compared between the groups.Results: Fifty‐one (24.4%) patients were clinically diagnosed with MM2‐type sCJD, of which 44 were diagnosed with MM2C‐type sCJD and 7 with MM2T‐type sCJD. In the absence of RT‐QuIC, 27 (61.3%) patients of MM2C‐type sCJD did not meet the US CDC sCJD criteria for possible sCJD on admission, even though the mean period from onset to admission was 6.0 months. However, all of these patients had cortical hyperintensity on DWI. Compared to the other types of sCJD, MM2C‐type sCJD was associated with slower disease progression and the absence of the typical clinical features of sCJD; the MM2T‐type sCJD group had a higher proportion of males, earlier age of onset, longer duration of disease, and a higher incidence of bilateral thalamic hypometabolism/hypoperfusion.Interpretation: In the absence of multiple typical sCJD symptoms within 6 months, the presence of cortical hyperintensity on DWI should raise concerns for MM2C‐type sCJD after excluding other etiologies. Bilateral thalamic hypometabolism/hypoperfusion may be more helpful in the clinical diagnosis of MM2T‐type sCJD.
- 6 June 2023
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 10 (7) , 1209-1218
Open AccessToward an early clinical diagnosis of MM2‐type sporadic Creutzfeldt–Jakob disease
Objective: To assess the proportion of clinically diagnosed MM2‐type sporadic Creutzfeldt–Jakob disease (sCJD) in a Chinese cohort, describe the clinical features of MM2‐cortical (MM2C) and MM2‐thalamic (MM2T) type sCJD to improve the early detection of MM2‐type sCJD.Methods: A total of 209 patients with sCJD admitted to the Xuanwu Hospital between February 2012 and August 2022 were reviewed. The patients were classified into probable MM2C, MM2T‐type sCJD, and other types of sCJD according to current clinical diagnostic criteria. Clinical and ancillary data were compared between the groups.Results: Fifty‐one (24.4%) patients were clinically diagnosed with MM2‐type sCJD, of which 44 were diagnosed with MM2C‐type sCJD and 7 with MM2T‐type sCJD. In the absence of RT‐QuIC, 27 (61.3%) patients of MM2C‐type sCJD did not meet the US CDC sCJD criteria for possible sCJD on admission, even though the mean period from onset to admission was 6.0 months. However, all of these patients had cortical hyperintensity on DWI. Compared to the other types of sCJD, MM2C‐type sCJD was associated with slower disease progression and the absence of the typical clinical features of sCJD; the MM2T‐type sCJD group had a higher proportion of males, earlier age of onset, longer duration of disease, and a higher incidence of bilateral thalamic hypometabolism/hypoperfusion.Interpretation: In the absence of multiple typical sCJD symptoms within 6 months, the presence of cortical hyperintensity on DWI should raise concerns for MM2C‐type sCJD after excluding other etiologies. Bilateral thalamic hypometabolism/hypoperfusion may be more helpful in the clinical diagnosis of MM2T‐type sCJD.
- 1 October 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (20) , 5543-5547
Novel steroidal saponins, Sch 725737 and Sch 725739, from a marine starfish, Novodinia antillensis
- 1 October 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (20) , 5543-5547
Novel steroidal saponins, Sch 725737 and Sch 725739, from a marine starfish, Novodinia antillensis